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Objective/Method: Aggrecanase activity, most notably ADAMTS-5, is implicated in pathogenic cartilage
degradation. Selective monoclonal antibodies (mAbs) to both ADAMTS-5 and ADAMTS-4 were generated
and in vitro, ex vivo and in vivo systems were utilized to assess target engagement, aggrecanase inhibition
and modulation of disease-related endpoints with the intent of selecting a candidate for clinical
development in osteoarthritis (OA).
Results: Structural mapping predicts the most potent mAbs employ a unique mode of inhibition by cross-
linking the catalytic and disintegrin domains. In a surgical mouse model of OA, both ADAMTS-5 and
ADAMTS-4-speciﬁc mAbs penetrate cartilage following systemic administration, demonstrating access to
the anticipated site of action. Structural disease modiﬁcation and associated alleviation of pain-related
behavior were observed with ADAMTS-5 mAb treatment. Treatment of human OA cartilage demon-
strated a preferential role for ADAMTS-5 inhibition over ADAMTS-4, as measured by ARGS neoepitope
release in explant cultures. ADAMTS-5 mAb activity was most evident in a subset of patient-derived
tissues and suppression of ARGS neoepitope release was sustained for weeks after a single treatment
in human explants and in cynomolgus monkeys, consistent with high afﬁnity target engagement and
slow ADAMTS-5 turnover.
Conclusion: This data supports a hypothesis set forth from knockout mouse studies that ADAMTS-5 is the
major aggrecanase involved in cartilage degradation and provides a link between a biological pathway
and pharmacology which translates to human tissues, non-human primate models and points to a target
OA patient population. Therefore, a humanized ADAMTS-5-selective monoclonal antibody (GSK2394002)
was progressed as a potential OA disease modifying therapeutic.
© 2015 The Authors. Published by Elsevier Ltd and Osteoarthritis Research Society International. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Translational drug development can be enhanced by addressing
a series of guiding principles throughout the pre-clinical stages of
development including: strategic drug design for the disease;. Larkin, Experimental Medicine Un
in).
r Ltd and Osteoarthritis Research Sdemonstration of target engagement and pharmacology within the
appropriate disease tissue; and co-development of mechanism-
related pharmacodynamic markers to assess efﬁcacy, identify
likely responders and guide dose selection. Although speciﬁc
criteria can be tailored for each target and therapeutic modality,it e Immuno-Inﬂammation Therapeutic Area Unit, GlaxoSmithKline, Upper Merion,
ociety International. This is an open access article under the CC BY-NC-ND license
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principles we aimed to produce selective aggrecanase (ADAMTS-4
and ADAMTS-5) inhibitors to guide selection of a disease-
modifying osteoarthritis drug (DMOAD).
OA is the most common form of arthritis and recent estimates
suggest that half of individuals over age 65 are affected1. Between
2002 and 2007, OA moved from the twelfth to the sixth leading
cause of years lost to disability or morbidity2, a trend that is ex-
pected to continue as the population ages and obesity rates rise. Yet
there are currently no proven disease modifying pharmacologic
therapies available.
Hallmarks of OA include cartilage destructionwith ensuing pain
and disability. Pathogenic cartilage degradation processes have
been a signiﬁcant research focus to identify key disease drivers and
develop novel treatments. Numerous cartilage degrading proteases
have been identiﬁed which may contribute to OA pathogenesis3. In
mouse models of arthritis, ADAMTS-5 is implicated in driving
cartilage loss and disease severity4,5, whereas, apart fromMMP-136,
other proteases did not contribute7.
Aggrecan, a primary aggrecanase substrate, is a key structural
component of cartilage. Intact aggrecan consists of N-terminal
globular domains, which anchor the glycoprotein to hyaluronic
acid, separated by a proteolysis-sensitive interglobular domain
(IGD) and a C-terminal region rich in glycosaminoglycan (GAG) side
chains important for maintaining cartilage elasticity, water content,
and structural integrity. Both aggrecanases and matrix metal-
loproteases (MMPs) are capable of cleaving within the IGD8,
resulting in release of the GAG-rich regions and contributing to loss
of structural integrity and impaired joint function. Notably, mice
possessing an aggrecanase-insensitive IGD mutation were pro-
tected from experimentally-induced OA and exhibit a pro-
regenerative phenotype9. In contrast, mice with an MMP-
insensitive IGD mutation showed no evidence of cartilage protec-
tion and appeared to have exacerbated disease9. Studies using
human OA tissues suggest that MMP activity is mainly associated
with normal turnover rather than pathogenesis10,11.
Taken together, these ﬁndings highlight a single axis in mice
which could be therapeutically targeted in human disease. How-
ever, translational uncertainty raises questions about the involve-
ment of ADAMTS-5 in the human condition. Although associations
between ADAMTS-5 and human OA have been made12e15, the link
remains controversial as other proteases have been
implicated3,14e18 and numerous proteases could conceivably
combine to drive disease progression. To this point the absence of
robust and selective inhibitors and redundancy in signatures of
aggrecanase activity havemade it difﬁcult to systematically address
these questions.
The goal here was to generate selective inhibitors to address
fundamental questions about the role of ADAMTS-4 and ADAMTS-5
in human OA and provide a foundation to develop a DMOAD. Fully
selective high afﬁnity monoclonal antibodies (mAbs) were assessed
for inhibition of recombinant and native aggrecanase activity,
target engagement, and modulation of disease endpoints in human
ex vivo and preclinical in vivo systems. Based on these studies it
appears that, as predicted by the knockout mouse, ADAMTS-5 is a
signiﬁcant protease involved in cartilage degradation in human OA
patients and a selected ADAMTS-5 inhibitor mAb (GSK2394002)
holds DMOAD potential.
Materials and methods
Binding speciﬁcity/afﬁnity
Antibody binding to plate-bound proteins was determined us-
ing immunoassays. Immunocytochemical binding of mAbs toBacMam transduced CHO cells19 was assessed using standard
chromogenic and microscopic detection techniques. Antibody/an-
tigen binding kinetics was measured using an OctetQK with
streptavidin biosensors (Fortebio) and analyzed using Octet anal-
ysis software.
Structural modeling
Crystal structures were acquired and antigen/antibody binding
was computationally modeled as described (Supplemental
Methods).
ARGS neoepitope detection
ARGS neoepitope was quantiﬁed using sandwich immunoassays
inDELFIA (inhibitionandexplant assay) orelectrochemiluminescent
(serum) format as described20 and Supplementary Methods.
ADAMTS-4 and ADAMTS-5 inhibition
Aggrecan mAb (Invitrogen, Cat# AHP0022) [100 ng] was
immobilized on assay plates overnight and bovine aggrecan
(Sigma) [10 nM] was subsequently bound for 60 min at 37C.
Sequential addition of treatment dose curves immediately pre-
ceded recombinant human ADAMTS-4 [1 nM] or ADAMTS-5 [1 nM]
to appropriate wells. Plates were incubated for 60 min at 37C to
allow treatment binding and the reaction to progress within the
linear phase of proteolysis and washed and detected with bio-
tinylated ARGS neoepitope mAb (OA-1)21, as described above. In-
hibition of proteolysis was quantiﬁed to compare relative potency
and graphed using Prism 5 software (GraphPad).
Human OA cartilage explant efﬁcacy
Tissues from total knee replacement (TKR) surgeries were
received within 24 h (NDRI, Philadelphia), processed and cultured
for assessment of treatment efﬁcacy as described in Supplemental
Methods. All human samples were sourced ethically and research
use was in accord with the terms of informed consents.
In vivo antibody penetration of cartilage
The destabilization of the medial meniscus (DMM) model of
OA22, was used to assess the ability of mAbs to engage the target
in vivo. Male Swiss Webster (SW) mice (Charles River) (12 weeks of
age at surgery) with established disease (6 weeks post-surgery)
were administered a single dose [16 mg/kg, IP] of IR800 dye
labeled mAb and periodically imaged using an Odyssey® system
(LI-COR) to conﬁrm accurate administration and monitor bio-
distribution. Mice were sacriﬁced 4 days after administration and
tissues processed for analysis. Dewaxed and rehydrated 7 mM knee
joint sections were imaged (Odyssey® and microscope equipped
with an IR800 ﬁlter set; Chroma).
In vivo OA mouse efﬁcacy
The DMMmodel22 was used to assess efﬁcacy in male SW mice
(12e16 weeks of age at surgery). Each group included 8e10 mice
with joint destabilization performed on each hind leg (n ¼ 16e20
knees/group). Age-matched naive and/or sham surgery (open the
joint capsule but no DMM) groups were included as negative
controls. Treated mice were pre-dosed with mAbs [16 mg/kg, IP]
3 days prior to surgery and once weekly throughout the 8 week
study. Efﬁcacy was assessed (readers blinded to treatment identity)
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pathological scoring system, as described22,23.
Non-human primate pharmacokinetic (PK)/pharmacodynamic (PD)
model
Healthy cynomolgus monkeys were screened for serum ARGS
neoepitope using the electrochemiluminescent immunoassay. An-
imals with the highest levels received intravenous or subcutaneous
GSK2394002 or vehicle control [50 mM sodium acetate buffer, pH
5.5 containing 1% (w/v) L-arginine, 0.05 mM EDTA, 51 mMNaCl and
0.02% (w/v) Tween™ 80 in sterile water for injection, USP]. All
animals were subsequently bled and monitored for pharmacoki-
netic and pharmacodynamic parameters. Serum ARGS neoepitope
was quantiﬁed and percent change from pre-dose calculated to
assess modulation of aggrecanase activity.
Statistical analysis
Statistical analysis using MannWhitney test is shown [Fig. 3(a)].
The total joint score [Fig. 5(a)] from each knee of the same animal
are correlated, so data was analyzed using repeated measure
analysis with compound symmetry (CS) within animal as covari-
ance matrix. The analysis incorporated correlations for knee ob-
servations arising from the same animal. Mechanical allodynia
[Fig. 5(b)] was assessed using a one-way ANOVA with Bonferonni
post-test. Non-parametric Mann Whitney test was performed to
compare baseline serum ARGS neoepitope between male and fe-
male monkeys [Fig. 6(a)]. Repeated measure analysis was used to
analyze the measurement of serum ARGS neoepitope percent
change from predose [Fig. 6(b)]. The repeated measure model
included dose, time, and dose by time interaction as ﬁxed effects
and subject as a random effect. Nomultiple comparison adjustment
method was used due to the research nature of the study. The
repeated measure analysis was performed in SAS 9.3 software.
Other analysis was performed in Prism 5 software.
Results
Monoclonal antibody generation and characterization
Multiple ADAMTS-4 or ADAMTS-5-selective mAbs were gener-
ated and tested for inhibition of aggrecanase activity and only those
demonstrating potent inhibition (using both puriﬁed bovine and
synthetic human peptide substrates) were characterized further.
Interestingly, individual mAbs that bound both ADAMTS-4 and 5
lacked functional inhibition. Two ADAMTS-5-speciﬁc mAbs, which
were subsequently humanized, and two ADAMTS-4-speciﬁc mAbs
were characterized for binding afﬁnity, selectivity, species cross-Table I
Characteristics of monoclonal antibody and small molecule aggrecanase inhibitors
Inhibitor Type Speciﬁcity Domain m
12F4.1H7 Mouse IgG2c ADAMTS-5 Cat/Dis
Humanized 12F4 (GSK2394002) Human IgG1 ADAMTS-5 Cat/Dis
7B4.1E11 Mouse IgG1 ADAMTS-5 Cat/Dis
Humanized 7B4 (GSK2394000) Human IgG1 ADAMTS-5 Cat/Dis
7E8.1E3 Mouse IgG1 ADAMTS-4 Cat/Dis
7C7.1H1 Mouse IgG2c ADAMTS-4 C-Terminu
GSK571949 Small Molecule Broad Spectrum Catalytic
Catalytic e amino acid sequence 262e484 of human ADAMTS-5 and 213e437 of human
Cat/Dis e catalytic þ disintegrin domains [262e576 human ADAMTS-5, 213e520 huma
C-Terminus e amino acid sequence 579e837 of human ADAMTS-4.reactivity, domain speciﬁcity and inhibition of aggrecanase activ-
ity (Table I and Fig. 1). Selectivity proﬁling demonstrates high target
speciﬁcity, as no binding was observed for a panel of related pro-
teases (ADAMTS-1 and 13), MMP-1, 3, 9 and 13 (not shown) and
unrelated controls [Fig. 1(a)e(d)]. In all species tested, the ability to
bind [Fig. 1(c) and (d)] and inhibit (not shown) the respective
protease was retained, suggesting structural conservation across
species consistent with the high (92%) sequence homology24.
Inhibitory potency (IC50) of mAbs against ADAMTS-4 or
ADAMTS-5-induced ARGS neoepitope formation was compared to
matched isotype control mAbs and a small molecule broad-
spectrum metalloprotease inhibitor (GSK571949)25. mAb
12F4.1H7 demonstrated a nearly 30-fold lower IC50 value for
ADAMTS-5 than the 7B4.1E11 clone [Fig. 1(f), 1.43 vs 41.26 nM],
consistent with the observed binding afﬁnity (Table I). In both
cases, humanization improved potency [Figs. 1(f), 0.83 vs 11.12 nM],
with the relative difference retained. Both ADAMTS-4 mAbs
demonstrated comparable IC50 for ADAMTS-4 [Fig. 1(e), 35 vs
48pM], which was lower than their binding afﬁnity (Table I)
potentially relating to the lower speciﬁc aggrecanase activity of
ADAMTS-426, inhibitor binding kinetics or concentration/speciﬁc
activity of protease used in the reaction. As a comparator,
GSK571949 demonstrated low nM functional inhibition of both
ADAMTS-4 and 5 [Fig. 1(e) and (f)]. ADAMTS-4 and ADAMTS-5 mAb
afﬁnities, measured using OctetQK (Table I) and BiaCore (not
shown) systems, ranged from low to mid pM. Consistent with
binding, selective inhibition was also maintained (not shown). The
differential functional potency between ADAMTS-5 mAbs may be
attributed to their respective off-rates (Kd). In addition, the hu-
manized 12F4.1H7 mAb (GSK2394002) dose-dependently sup-
pressed ADAMTS-5-mediated proteolysis of aggrecan and brevican
suggesting its inhibition is not substrate-selective (Supplementary
Figure 1).
Domain mapping, using truncated forms of each protease
(Table I and Fig. 1(b)) and competitive mAb binding assays (not
shown), suggest that 12F4.1H7 and 7B4.1E11 recognize a similar
epitope within the catalytic and disintegrin domains (amino acids
262e576). Both mAbs failed to bind recombinant catalytic domain
(amino acids 262e484) in this assay. The ADAMTS-4 mAb domain
speciﬁcity was distinct, with 7E8.1E3 recognizing the
catalytic þ disintegrin domain (like the ADAMTS-5 mAbs) and
7C7.1H1 a C-terminal epitope between amino acids 579e837
(Table I) possibly highlighting a substrate-binding exosite.
Efforts to further deﬁne epitopes employed crystal structures of
ADAMTS-4 (PDB: 3B2Z) and ADAMTS-5 with mAb-derived Fab
fragments (PDB: 4X80 and 4X8J) in a computational docking pre-
diction model27. This approach was taken because co-
crystallization attempts failed to produce crystals suitable for X-
ray diffraction. Interestingly, mAbs mapping to theapping Afﬁnity Neutralization IC50 (nM)
Ka [1/Ms] Kd [1/S] KD
6.99E þ 04 2.49E  06 0.035 nM 1.46
7.54E þ 04 2.88E  06 0.038 nM 0.83
9.25E þ 04 2.59E  05 0.280 nM 41.26
1.06E þ 05 2.16E  05 0.205 nM 11.12
2.81 E þ 05 7.08E  05 0.252 nM 0.035
s 2.01 E þ 06 5.72E  04 0.285 nM 0.048
5.73 ADAMTS-4
9.67 ADAMTS-5
ADAMTS-4.
n ADAMTS-4].
Fig. 1. ADAMTS-4 and ADAMTS-5mAbs speciﬁcally bind to and potently inhibit aggrecanase activity. (a) Selective binding ofmAbs for ADAMTS-4 (7E8.1E3) and ADAMTS-5 (7B4.1E11)
is demonstrated by immunocytochemistry using ADAMTS-4, ADAMTS-5 and Null BacMam transduced CHO cells. ADAMTS-5 speciﬁc domain mapping and selective binding to
puriﬁed recombinant proteins is proﬁled by ELISA (b; 12F4.1H7) and DELFIA (c; 7E8.1E3 and d; 12F4.1H7) (Results shown are n ¼ 2 independent experiments with two dependent
replicates for each concentration ± 95% CI). Functional potency of ADAMTS-4 (e) and ADAMTS-5 (f) mAbs and non-selective small molecule (GSK579149) is quantiﬁed vs isotype
controls (not shown) by measuring percent inhibition of selective aggrecanase-mediated ARGS neoepitope formation from puriﬁed bovine aggrecan substrate. IC50 values for each
mAb and GSK571949 are shown (inset, e and f) in relation to isotype control mAbs and DMSO, respectively, which did not demonstrate any detectible inhibitory activity. Consistent
with binding speciﬁcity, no inhibition of aggrecanase activity was observed in this assay for ADAMTS-4 with ADAMTS-5 mAbs and ADAMTS-5 with ADAMTS-4 mAbs (not shown).
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conformational epitope spanning these two domains [Fig. 2(a) and
(b)] and may derive activity from ‘allosterically locking’ the do-
mains together. Comparing ADAMTS-5-speciﬁc mAbs [Fig. 2(b)],
the number of predicted high-energy (hydrogen bond) interactions
was greater for GSK2394002 compared to GSK2394000 (13 vs 6
sites, Fig. 2(c)), consistent with the differential afﬁnity and inhibi-
tion. Furthermore, binding was spread across the heavy and light
chain of each mAb with interactions outside the complementarity
determining region (CDRH3) that deﬁnes classical antibody
speciﬁcity28.Human OA cartilage explant efﬁcacy
Cartilage explants from human OA patients at TKR were utilized
to directly compare the role of ADAMTS-4 and ADAMTS-5 in
cartilage degradation. Pharmacology was assessed by measuring
inhibition of ARGS release, as a marker of aggrecanase activity, in
the presence of ADAMTS-speciﬁc and isotype control mAbs
(670 nM [100 mg/mL]) or GSK571949 (2 mM). These studies were
performed longitudinally with a 3-week unstimulated phase, fol-
lowed directly by 1-week of cytokine stimulation. A total of 13e28
individual OA donors were assessed for each treatment to
J. Larkin et al. / Osteoarthritis and Cartilage 23 (2015) 1254e12661258compensate for inter-patient variability and each condition was
performed on seven replicate cartilage plugs from each donor to
reduce intra-patient variability.
In the unstimulated phase, ADAMTS-5 mAbs potently sup-
pressed ARGS release compared to isotype controls [Fig. 3(a)], while
ADAMTS-4 mAbs had only a modest effect, suggesting that
ADAMTS-5 is the predominant ARGS-producing aggrecanase in
cartilage from these patients. Combination of ADAMTS-4 and
ADAMTS-5 mAbs (7E8.1E3 and 7B4.1E11 respectively) at equimolar
concentrations (670 nM each) showed no beneﬁt over ADAMTS-5
mAbs alone (data not shown). Although ADAMTS-4 mAb inhibi-
tion increased following exogenous cytokine stimulation, ADAMTS-
5 mAbs retained similar activity suggesting a potential role for both
ADAMTS-4 and ADAMTS-5 under this condition. Subsequent
studies titrating GSK2394002 in cartilage explants with elevated
pre-treatment ARGS levels demonstrated dose-dependent inhibi-
tion which was nearly complete at concentrations 670 nM
[Fig. 3(b)].
The premise that endogenous aggrecanase activity could iden-
tify patients most likely to respond to ADAMTS-5 mAb treatment
framed experiments designed to support a personalized medicineFig. 2. In silico structural modeling of antigen/antibody interactions suggest a conformation
which spans the catalytic and disintegrin domains of each protease and predicts an ‘alloster
shown; cyan/light blue is the light chain and magenta/purple the heavy chain of the mAbs
Individual and merged overlay structural models of the inhibitory ADAMTS-5 mAbs (b) an
predicted to form hydrogen bond interactions (GSK2394000, six bonds and GSK2394002, t
scan of the predicted protease/mAb interface (c).strategy. In these studies, endogenous ARGS levels were quantiﬁed
in individual patient explant cultures (n ¼ 16) prior to treatment
with GSK2394002 or an isotype control mAb followed by longitu-
dinal assessment of inhibition. Only half of the individual patient
explants demonstrated elevated pre-treatment ARGS levels
(Supplementary Figure 2), suggesting distinct phenotypes exist
related to endogenous aggrecanase activity in this system, which
may correlate to observations made in patients20. The response to
GSK2394002 treatment correlated with pre-treatment ARGS levels
[Fig. 3(c)] while isotype control treatment had little effect
(Supplementary Figure 2), suggesting a predominant role for
ADAMTS-5-mediated aggrecanolysis at the IGD cleavage site in
these patients.
Duration, potency and reversibility of this responsewere further
evaluated using cartilage with elevated pre-treatment ARGS levels
and a pulse-chase treatment method. GSK2394002 produced sus-
tained ARGS inhibition [Fig. 3(d)] compared to isotype and
GSK571949 treatment. These data are consistent with high afﬁnity
binding and slow off-rate for GSK2394402 and suggests a modest
rate of endogenous ADAMTS-5 turnover in this system. In contrast,
GSK571949-treated cultures appeared to steadily lose inhibitoryal binding epitope for select ADAMTS-4 (7E8.1E3) and ADAMTS-5 (GSK2394002) mAbs
ic lock’ mechanism of inhibition (a). In all panels the top ranked docking orientation is
; orange is the catalytic domain and green the disintegrin domain of ADAMTS-4 or -5.
d amino acid residues spanning the catalytic and disintegrin domains of ADAMTS-5
hirteen bonds) are shown with bond energy predictions from an Alanine substitution
Fig. 2. (continued).
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Fig. 3. Potent and sustained inhibition of aggrecanolysis fromhumanOA cartilage explants by ADAMTS-5mAb treatment. ADAMTS-5mAb treatment inhibits ARGS neoepitope release
from sequentially unstimulated and IL-1b/OSMstimulated humanOA cartilage explants (a), whereas onlymodest inhibition is observedwith ADAMTS-4mAb treatment, preferentially
under cytokine-stimulated conditions. Mean percent inhibition of mAbs is shown relative to isotype control mAb (0% inhibition, dashed lines in a and b) and GSK571949 (100%
inhibition) treatment. Experiments were conducted with seven replicates for each treatment condition from eight timepoints across multiple 28-day experiments consisting of a 21
day unstimulated phase followed by a 7-day cytokine-stimulated phase. A total of 13e28 independent OA patient experimentswere conducted for each treatment condition. ADAMTS-
4 (7E8.1E3 or 7C71.H1) and ADAMTS-5 (12F4.1H7 or 7B4.1E11) mAb treatments are shown as compiled data associated with each mAb speciﬁcity. All mAb treatments were held
constant at 670 nM throughout the experiment and GSK571949 was similarly held at 2 mM. (b) Dose-dependent inhibition of ARGS neoepitope release is evident with GSK2394002
treatment in the absence of exogenous cytokine stimulation using cartilage from individual OA donors with elevated pre-treatment ARGS neoepitope levels (n ¼ 2e8 independent
donor experiments per treatment concentration and each point represents mean % inhibition from 21 day unstimulated phase, as described in (a)). Plots (a and b) are presented in
standard box-and-whisker format with Tukey outliers noted (>1.5 times IQR, ﬁlled symbols). (c) Linear regression analysis suggests the response to GSK2394002 treatment correlates
with pre-treatment ARGS neoepitope levels. Sustained suppression of ARGS neoepitope release is observed with pulse-chase GSK2394002 treatment in relation to small molecule
(GSK571949) in individual donor experiments using cultureswith elevated pre-treatment ARGS neoepitope levels (n¼ 4; each timepoint and±95% CI error bar representsmean of four
independent donor experiments where seven biological replicates for each donor/timepoint was used to calculate a within donor mean for each timepoint) (d).
J. Larkin et al. / Osteoarthritis and Cartilage 23 (2015) 1254e12661260activity as the experiment progressed, demonstrating a transient
drug/target interaction.
In vivo target engagement and therapeutic efﬁcacy
The ability of mAbs to engage their respective targets in vivowas
assessed using labeledmAbs in a preclinical OAmodel. Imaging and
microscopic techniques were employed to monitor biodistribution
and cartilage penetration. For continuity, the dose [16mg/kg], route
(IP), mouse strain (SW) and disease model (DMM) was the same
used for in vivo efﬁcacy assessments. Whole body imaging imme-
diately after dosing and again at day 4 conﬁrmed accurate delivery
and systemic biodistribution [Fig. 4(a)]. ADAMTS-4 and ADAMTS-5
mAb treated mice showed a systemic signal on day 4, consistent
with dermal deposition, a site of reported expression29. Consistent
with enabling human cartilage experiments (not shown) and
literature reports30 suggesting time-dependent ex vivo mAb
penetration of cartilage, in vivo target engagement was observedwithin 4 days [Fig. 4(b)e(e)]. Characteristic pericellular staining
patterns within the cartilage noted for both ADAMTSs13 were
observed [Fig. 4(d)e(e), inset] and ADAMTS-5 mAb intensity was
qualitatively greater than the ADAMTS-4 mAb and exhibited su-
perﬁcial zone cartilage layer, meniscus and subchondral bone sig-
nals [Fig. 4(d)e(e)].
In vivo efﬁcacy was assessed histologically in DMMmice treated
with ADAMTS-5 speciﬁc mAbs or isotype controls in two inde-
pendent studies (Fig. 5). A prophylactic/weekly treatment regimen
was chosen to validate ADAMTS-5 knockout ﬁndings4. Pharmaco-
kinetic studies using 12F4.1H7 suggests this regimen should
maintain circulating concentrations >100 mg/mL throughout the
study. Both naïve (mean 14.81 ± 5.37) and sham surgery control
groups (15.13 ± 2.85 and 15.58 ± 3.63 in each respective study) had
comparable joint scores. Whereas isotype control mAb treated
(24.88 ± 4.18 and 28.53 ± 7.10) and untreated mice (24.63 ± 6.46)
suggest substantial joint damage at 8 weeks after DMM. Alterna-
tively, both ADAMTS-5 mAbs independently imparted statistically
Fig. 4. ADAMTS-4 and ADAMTS-5 mAbs engage their targets within the cartilage following systemic administration in a mouse OA model. IR800-labeled ADAMTS-4 (7E8.1E3),
ADAMTS-5 (7B4.1E11) or Isotype control mAbs were administered ([16 mg/kg] IP) to mice (n ¼ 1/group) 6 weeks after surgical destabilization of the medial meniscus and peri-
odically imaged to monitor systemic biodistribution and tissue penetration. Within 30 min of dosing a strong IR800 signal (green) can be observed in the abdomen of all animals (a,
left) indicative of accurate administration. The red abdominal signal is related to the inherent infrared signature of the animal diet traversing the digestive system. Systemic IR800
signal is observed in mice receiving ADAMTS-4 or ADAMTS-5 mAb (and to a much lesser extent the isotype control treated animal) 4 days following administration (a, right) when
the animals were sacriﬁced to assess tissue distribution. The right hind leg of each animal is shown (b) with skin removed showing a strong signal intensity in the joint region of the
ADAMTS-5 mAb treated mouse (red arrowhead) compared to the other treatments. Similar qualitative differences between treatment groups can be observed in low (c; 4
magniﬁcation) and high power (def; 200 magniﬁcation) images of the knee joint, as well as evidence for cartilage penetration and deposition in the cartilage for the ADAMTS-4
and ADAMTS-5 mAbs in the superﬁcial cartilage zone and pericellular region of the articular chondrocytes (dee, inset). Merged microscopic bright-ﬁeld/IR800 images are shown. In
the ADAMTS-5 mAb panel (e) staining in the meniscus can be observed (bottom half of image). No signal was observed following administration of a labeled isotype control mAb (f)
or following administration of a non-reactive dye control, which was undetectable within 24 h after dosing (not shown).
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20.28 ± 5.64 and 22.69 ± 6.66 [12F4.1H7 and 7B4.1E11, study 2
respectively]) (Fig. 5). Representative images of toluidine blue
stained knees, aligned with mean group scores, are shown. In a
separate study, ADAMTS-4 mAbs failed to protect from progression
of joint damage (not shown).
In addition to protection from joint damage, an independent
study assessed development of mechanical allodynia as a pain-
related behavior associated with OA31 employing the DMM model
in C57BL/6 mice. Throughout the course of the 8-week study, mice
treated prophylactically with 7B4.1E11 were protected from me-
chanical allodynia [Fig. 5(b)], consistent with ADAMTS-5 deﬁcient
mice31. Eight weeks post-surgery, mice showed fewer F4/80 mac-
rophages in innervating dorsal root ganglion32 compared to un-
treated and isotype control mAb treated mice [Fig. 5(c)].Non-human primate PK/PD model
Cynomolgus monkeys were utilized to assess fundamental PK/
PD effects of GSK2394002 treatment on circulating ARGS levels as a
predictor of target inhibition and translational dose selection.
Although not an experimental disease model, cynomolgus mon-
keys naturally develop a condition consistent with OA33. In this
study, 31 individual animals were pre-screened for circulating
ARGS as an indicator of endogenous aggrecanase activity
(Supplementary Table 1). Interestingly, male monkeys typically had
higher levels than females [Fig. 6(a)]. Signiﬁcant correlations were
also observed between ARGS with both age and weight in males,
but not females (Supplementary Table 2).
GSK2394002-treated animals exhibited a rapid and sustained
reduction in circulating ARGS neoepitope, while levels remained
Fig. 5. ADAMTS-5 mAb treatment suppresses joint disease severity in a mouse model of OA. Mice treated prophylactically with anti-ADAMTS-5 (1x/week, i.p. 10e16 mg/kg) were
protected from developing (a) histologic cartilage degeneration (two independent studies shown, n ¼ 8e10 animals/group each with two DMM knees/animal, although not all
knees in study two could be scored due to isolated tissue processing errors and in one group loss of a single mouse between surgery and treatment commencement, as
demonstrated by individual knee symbols in each group ranging from 15 to 19/group). Representative toluidine blue stained knee joint sections are shown for each study group. (b)
Mice treated prophylactically with anti-ADAMTS5 mAb (1x/week, i.p. 10 mg/kg) were protected from developing mechanical allodynia through 8 weeks post DMM, ***P < 0.001 vs
time 0, n ¼ 12/group. Mean ± 95% CI. (c) Prophylactic treatment with anti-ADAMTS5 mAb also protected mice from macrophage inﬁltration (F4/80 marker) into the DRG at 8 weeks
post DMM. Arrows indicate examples of inﬁltrating macrophages in the DMM control and Isotype control mAb (IgG1) conditions.
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GSK2394002 administration decreased ARGS levels within 3 days
relative to pre-dose values (approximately 50e70% dose-
dependent reduction) and remained suppressed throughout the
study monitoring period with twice-monthly administration (in-
dividual animal reduction relative to pre-dose of 50e75% at 30 mg/
kg, ~60e70% at 100 mg/kg and ~70e90% at 300 mg/kg). Alterna-
tively, individual vehicle control treated animals remained within~65e138% of pre-dose levels. Circulating GSK2394002 levels
observed following administration were consistent with PK pre-
dictions and no immunogenicity was observed (not shown).
Discussion
Strategic drug discovery typically relies on a diverse combina-
tion of data to validate a disease target and provide a translational
Fig. 6. a) e Male cynomolgus monkeys exhibit generally higher endogenous circulating ARGS neoepitope concentrations as compared to females. (b) e Serum ARGS neoepitope
levels rapidly and dose-dependently decline in response to ADAMTS-5 mAb (GSK2394002) treatment in non-human primates. Monkeys (n/group at each timepoint is shown from
two independent studies, both males and females included at each timepoint except days 14e28 which is only females) were dosed every 2 weeks starting immediately after a pre-
dose blood sample at day 0. Serum and plasma was drawn on the third day after dosing, immediately prior to the next dose and periodically throughout the study as shown to
monitor circulating PK and PD endpoints. Mid study samples were not taken for the 100 mg/kg group and some animals in the other groups, as shown. Data represents mean
percent change from pre-dose ± 95% CI with statistical signiﬁcance (∞P ¼ 0.023, %P ¼ 0.0046, #P ¼ 0.0027, VP ¼ 0.0001 *P < 0.0001) observed for all GSK2394002 dose groupings
and at all post-treatment timepoints relative to the vehicle control treated group.
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biology between species, selectivity of tools used to modulate
target activity and methods to model a disease state frequently
create uncertainty about accurate translation to the human con-
dition. Due to conﬂicting reports on the role of ADAMTS-4 and
ADAMTS-5 in models of murine4,5 and human15,17 OA, we set out to
generate selectivemonoclonal antibody inhibitors to gain clarity on
this discrepancy and guide a human DMOAD strategy.
Here, we demonstrate characterization and validation of selec-
tive and potent inhibitorymAbs targeting ADAMTS-4 and ADAMTS-
5 in numerous in vitro, ex vivo, in silico and in vivomodels of efﬁcacy,
target engagement and pharmacology. Although numerous reports
of aggrecanase inhibitors exist25,34,35, we believe this is the ﬁrst
example of a direct comparison of fully selective inhibitors with
sub-nanomolar potency. The proposed novel ‘allosteric lock’
mechanism of action suggested for some of the mAbs described
here (Fig. 2) supports the observed selective neutralization of
protease activity and appears distinct from other metalloprotease
neutralizing mAbs which largely target the catalytic active site
directly and frequently lack full selectivity36,37. We propose this
selectivity proﬁle can be attributed to these unique epitopes and
provides a basis for the ‘allosteric lock’ model where an antibody
simultaneously binding the catalytic and disintegrin domains im-
pairs inherent protease ﬂexibility and inhibits its ability to engage
and cleave substrate38. Although understanding the mechanism of
inhibition is not required for therapeutic development, it can pro-
vide insight into selecting a clinical candidate and set a strong
foundation for securing intellectual property.
The translational role of ADAMTS-4 and ADAMTS-5-selective
mAbs was assessed in human OA cartilage explants. Admittedly,
this system is cartilage-centric and excludes other tissues of this
total joint disease, such as bone, synovium, meniscus and adipose
tissue, which may contribute to pathogenesis. However, as
endogenous aggrecanase activity was routinely observed, the
explant model provides a relevant system to assess the mecha-
nisms in question. Aggrecanase activity leading to ARGS neoepitope
generation is important in both mouse9 and human8,14 disease and,
although both ADAMTS-4 and ADAMTS-5 are capable of cleaving
there (Fig. 1 and 39), ADAMTS-5 has been shown to have signiﬁ-
cantly greater activity for this site11. The human explant model was
performed with and without exogenous cytokine stimulation,
although our view is that the unstimulated phase, whereendogenous factors are allowed to persist in culture, is more
representative of native disease. Exogenous cytokine stimulation,
which clearly accelerates cartilage degradation, emphasizes spe-
ciﬁc inﬂammatory mediators with unclear disease relevance that
may bias data interpretation. Our data show markedly greater ef-
ﬁcacy with ADAMTS-5 mAb treatment compared to ADAMTS-4
mAbs in the unstimulated phase [Fig. 3(a)] supporting a predomi-
nant role for ADAMTS-5 in this system.We cannot rule out a role for
ADAMTS-4, as a modest level of inhibition with the ADAMTS-4
mAbs was observed in a subset of patients and suggests an
ADAMTS-4 contribution where IL-1 and OSM are involved
[Fig. 3(b)]. Notably however, combining both ADAMTS-4 and
ADAMTS-5 mAbs at ﬁxed equimolar concentrations did not in-
crease inhibition above the ADAMTS-5 mAbs alone (not shown)
and higher doses of GSK2394002 were capable of complete inhi-
bition in some patient samples [Fig. 3(b)]. This is consistent with
single (ADAMTS-5) and dual (ADAMTS-4/5) knockout animal
ﬁndings4,40.
In contrast, efforts using siRNA-mediated inhibition in human
OA cartilage suggest both aggrecanses play a role17. Potential ex-
planations for this apparent discrepancy may relate to differential
mechanistic inhibition between mAbs and siRNA inhibitors, which
could be important considering ADAMTS-4 and ADAMTS-5 have
distinct transcriptional regulation41. The selective mAbs may not
inhibit an isoform or other aggrecanase, as numerous variants have
been noted for ADAMTS-4 and ADAMTS-5 in human OA cartilage
samples42,43 and ADAMTS-4/5 dual knockout mice retain residual
aggrecanase activity44. Finally, target engagement for each mAb in
human cartilage explants may differ and was not independently
assessed in all cases.
Due to the dense nature of cartilage and large size of antibodies,
a widely held perception is that mAbs are unable to penetrate the
cartilage matrix. Expression proﬁles for ADAMTS-4 and ADAMTS-5
localize to the pericellular region of chondrocytes in human OA
cartilage13. Therefore, in order to be effective, aggrecanase-speciﬁc
mAbs may need to penetrate cartilage. Prior reports using mAbs
and hyaluronan demonstrate in vitro penetration of large proteins
in osteoarthritic, and to a lesser extent normal, cartilage30. Wewere
able to conﬁrm these ﬁndings. However, the process of preparing
tissue for culture and disease state may render the cartilage sam-
ples more amenable to penetration. Therefore, demonstrating
in vivo target engagement within cartilage was important (Fig. 4).
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endpoints observed in the same model and dose levels (Fig. 5),
these data strongly suggest effective in vivo target engagement.
Interestingly, increased proteoglycan staining seems apparent in
ADAMTS-5 mAb treated mice [Fig. 5(a)] compared to controls.
Although this may be a result of a chondrogenic activity of these
highly potent inhibitors, it may likely be a result of inhibiting
normal physiologic turnover of aggrecan leading to accumulation.
Therefore, careful consideration of dose and frequency of admin-
istration may be warranted.
Building upon these ﬁndings, translational PK/PD dos-
eeresponse relationships in non-human primates may aide human
clinical development and are particularly relevant due to similar-
ities in physiology, target homology and lower propensity to
develop anti-drug antibodies. These studies clearly demonstrate a
potent in vivo modulation of aggrecanase activity [Fig. 6(b)] and
provide conﬁdence in the pharmacologic effect of ADAMTS-5 mAb
treatment. Moreover, cynomolgus monkeys naturally develop an
age-related condition similar to OA33,45 and elevated circulating
levels of ARGS neoepitopewere observed in a subset of animals that
correlate with age and weight (Supplementary Table 2) suggesting
a level of consistency with human OA20. The observed gender dif-
ferences in circulating ARGS levels are interesting, although they
seem to differ from the human condition where females have an
increased incidence of OA. It is conceivable that hormones could
contribute to this apparent discrepancy especially when consid-
ering female OA patients are typically post-menopausal.
In summary, clear preclinical links to the therapeutic mecha-
nism are demonstrated through applying fundamental trans-
lational principles for therapeutic development in ex vivo human
and in vivomodels with a sensitivemeasure of aggrecanase activity.
Ultimately, ARGS may be used in conjunction with GSK2394002 or
other drugs to assess clinical parameters of efﬁcacy and patient
stratiﬁcation to prospectively identify those most likely to respond
to treatment. Numerous reports describe similar assays and com-
parisons to small molecule efﬁcacy in rodent systems with similar
results46,47. However, this is the ﬁrst report utilizing fully selective
pharmacologic ADAMTS-4 and ADAMTS-5 inhibitors and non-
human primates to assess the link.
Together, the current ﬁndings are consistent with foundational
knockout mouse studies suggesting a predominant role of
ADAMTS-5 in osteoarthritic cartilage degradation and allodynia
further providing a justiﬁcation for clinical development of
GSK2394002. However, prior to initiating clinical trials, additional
studies are necessary to predict safety and tolerability of
GSK2394002 and whether, as some recent reports suggest29,48e50,
inhibition of ADAMTS-5 may lead to undesired effects in other
tissues.Contributions
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